These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12053421)

  • 1. Antipodean assessment. Activities, actions, and achievements.
    Mitchell AS
    Int J Technol Assess Health Care; 2002; 18(2):203-12. PubMed ID: 12053421
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 4. Health technology assessment in Australia: challenges ahead.
    Jackson TJ
    Med J Aust; 2007 Sep; 187(5):262-4. PubMed ID: 17767428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.
    Hailey D
    Soc Sci Med; 1997 Aug; 45(4):563-81. PubMed ID: 9226782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective.
    Earnshaw J; Lewis G
    Pharmacoeconomics; 2008; 26(9):725-7. PubMed ID: 18767892
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessment and economic evaluation across jurisdictions.
    Simoens S
    Value Health; 2010; 13(6):857-9. PubMed ID: 20701730
    [No Abstract]   [Full Text] [Related]  

  • 11. Health technology assessment: reflections from the Antipodes.
    Bulfone L; Younie S; Carter R
    Value Health; 2009 Jun; 12 Suppl 2():S28-38. PubMed ID: 19523182
    [No Abstract]   [Full Text] [Related]  

  • 12. Merging regulatory and reimbursement needs in clinical trials.
    Cook JR
    Value Health; 2015 Mar; 18(2):145-6. PubMed ID: 25773549
    [No Abstract]   [Full Text] [Related]  

  • 13. Health economic guidelines--similarities, differences and some implications.
    Hjelmgren J; Berggren F; Andersson F
    Value Health; 2001; 4(3):225-50. PubMed ID: 11705185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

  • 15. Health technology assessment. The pharmaceutical industry perspective.
    Schubert F
    Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From principle to public policy: using cost-effectiveness analysis.
    Neumann PJ; Johannesson M
    Health Aff (Millwood); 1994; 13(3):206-14. PubMed ID: 7927151
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of cost-effective nuclear medicine practice in Japan.
    Sasaki Y
    Acad Radiol; 1996 Apr; 3 Suppl 1():S106-8. PubMed ID: 8796530
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Getting to 'smart' health care.
    Clancy CM
    Health Aff (Millwood); 2006; 25(6):w589-92. PubMed ID: 17090557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health technology assessment and economic evaluation: arguments for a national approach.
    Vale L
    Value Health; 2010; 13(6):859-61. PubMed ID: 20701729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.